Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab adjunctive treatment for schizophrenia
ACTRN12615000635561Phase 4Completed
- Sponsor
- Neuroscience Research Australia
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing Canakinumab adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoints: Positive and Negative Syndrome Scale total score at 4 months, Positive and Negative Syndrome Scale positive symptoms score at 4 months and 1 more. Started Jun 2015; status: completed.
02
Drugs
canakinumab
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on ACTRN12615000635561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000635561.